Soluble Cluster of Differentiation 160 (sCD160) in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies

Sponsor
CHU de Reims
Study ID
NCT03680794
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • sampling of ophthalmic liquid — OTHER
    aqueous sampling for patients with cataract surgery or vitreous sampling for patients with posterior segment surgery

Study Details

CD160 represents a new angiogenic factor as its specific engagement by an agonist monoclonal antibody directed against human CD160 reduced angiogenesis of endothelial cells with a distinct mechanism from current angiogenic therapies that target the VEGF/VEGF-R pathway. A soluble form of CD160, sCD160, has been found to be highly expressed in the vitreous and the sera of patients with severe diabetic retinopathies, and can now be dosed with help of an ELISA test. The investigators aim to evaluate the association between ischaemic retinopathies (patients with or without) and sCD160 concentrations in the vitreous, the aqueous humour and the serum.

Key Dates

First listed
Sep 21, 2018
Start date
Jun 27, 2018
Status verified
Apr 2026
Primary completion
Dec 27, 2027
Completion
Feb 27, 2028

Study Design

Enrollment
120 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Experimental: Patients with ophthalmic surgery

Primary Outcome Measure

sCD160 concentration in the vitreous humor [ Time Frame: Day 0 ]

Central Contacts

Find similar trials

Nationwide
Diabetic retinopathy trialsOphthalmology trialsRetina trials

Related Studies